Kawaguchi et al. measured decorin in 65 HCC patients indicated for transcatheter arterial chemoembolization therapy and divided them into two groups according to the median value of decorin: high-decorin group and low-decorin group, and examined physical function and prognosis. The gene discussed is DCN; the disease is hepatocellular carcinoma.